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Background
Identification of promiscuous antigenic regions is crucial
for the design of an epitope-based vaccine. Still, the qual-
ity of the responses has been under estimated in most
cases when only IFN-γ is used to measure anti-HIV cellular
immunity. Luminex multiplexing system allows the iden-
tification of T cell responses characteristic of T cell sub-
types through their secretion of not only Th1/CTL but
other important sets of cytokines, including IL-5, Il-10, Il-
13, IL-21 and IL-17.
Methods
We have studied the full spectrum of Nef-specific T cell
memory recall responses in chronically infected HIV
patients on HAART expressing a broad spectrum of HLA
types. Briefly, short-term PBMC cultures were stimulated
with 15-mer overlapping peptides from Nef in the pres-
ence of IL-2, conditions which favor expansion of antigen-
specific T cells. Luminex analysis of the culture superna-
tants were used for simultaneous identification of a
diverse array of peptide-specific cytokine profiles.
Results
We observed strong Th1/CTL responses against two previ-
ously described highly immunogenic regions in the cen-
tral Nef sequence: Nef 67–101 and Nef 103–148. All of
the 16 patients that we analyzed responded to peptides
from one or both regions by secreting IFN-γ and TNF-α.
However, Th2 responses (IL-5, IL-13) against peptides
covering the Nef 67–97 were observed in half of the
patients. This region is also able to stimulate Th1/CTL spe-
cific cells. Interestingly, we also observed high levels of IL-
17 secretion in 7 out of 16 patients in response to at least
one peptide, yet no specific region in the protein could be
associated with IL-17 responses.
Conclusion
In order to design new vaccines we need a deep under-
standing of both the quantity and quality of the responses
induced by any antigen. A more complete study of T cell
responses to HIV antigens is essential for the selection of
epitopes that should be included in future trials.
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